Here's why the Immuron (ASX:IMC) share price is rocketing 31% today

The company's shares are one of the best performers on the ASX today.

| More on:
a man raises his fists to the air in joyous celebration while learning some exciting good news via his computer screen in an office setting.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Immuron Ltd (ASX: IMC) share price is shooting out the lights on Wednesday following a positive update from the company.

At the time of writing, the biopharma company's shares are swapping hands for 12.2 cents, up 31.18%.

A clinical-stage medical company, Immuron is focused on the development and commercialisation of a novel class of specifically targeted polyclonal antibodies. The company researches and develops hyperimmune products for markets in Australia, the United States, and Canada.

Product sales comprise Travelan and Protectyn, used for the prevention of travellers' diarrhoea.

Let's take a look at the company's latest news…

What did Immuron announce?

Investors are buying up Immuron shares after the company announced funding on a new research agreement.

According to its release, Immuron advised it has been awarded funding from the United States Department of Defence for Travelan. This will be aimed at examining a dosing regimen of the oral immunotherapeutic for use by the military.

In total, US$4.45 million (A$6.2 million) will be allocated to conduct a controlled human infection model (CHIM) clinical trial.

Up to 60 volunteers will be enrolled in the study. They will be randomly selected to receive either a once-daily dose of 1200 mg of Travelan or placebo.

The results of the trial will also provide information on dosing in the future Phase 3 registration trials.

Immuron noted that a project meeting has been scheduled for the end of January with the US government sponsors.

Infectious diarrhea is the most common illness reported by travellers visiting developing countries and among US troops deployed overseas. The morbidity and associated discomfort stemming from diarrhea decreases daily performance, affects judgment, decreases morale, and declines operational readiness.

While the first line of treatment for infectious diarrhea is the prescription of antibiotics, this has waned over the last decade. Several enteric pathogens have evolved to become increasingly resistant to commonly prescribed antibiotics.

Immuron CEO Dr Jerry Kanellos commented:

This new project expands our clinical development program and represents the first of several significant clinical trials which the company expects to undertake with the US Military in 2022.

…The new funding is testament to the value proposition our hyperimmune bovine polyclonal colostrum technology offers to benefit the U.S. Military as well as the civilian international travelling population.

Immuron share price snapshot

A disappointing 12 months has led Investors to recorded losses of almost 60% on the Immuron share price. In the past month alone, the company's shares have declined around 20%, highlighting a strong downward trend since July 2020.

Based on today's boosted share price, Immuron has a market capitalisation of roughly $28 million, with approximately 227 million shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »